These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6794745)

  • 21. [Hypoglycemic agents of the 2d generation].
    Giulietti M
    Clin Ter; 1978 Jul; 86(2):179-81. PubMed ID: 743858
    [No Abstract]   [Full Text] [Related]  

  • 22. [Efficacy of gliclazide in short and long-term therapy of older persons with noninsulin-dependent diabetes].
    Djurić DS; Djordjević PB; Micić D; Dragasević M
    Srp Arh Celok Lek; 1981 Nov; 109(11):1503-9. PubMed ID: 7051354
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.
    Noury J; Nandeuil A
    Diabete Metab; 1991 May; 17(1 Pt 2):209-12. PubMed ID: 1936478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of long term gliclazide administration on insulin secretion and insulin sensitivity.
    Ma A; Kamp M; Bird D; Howlett V; Cameron DP
    Aust N Z J Med; 1989 Feb; 19(1):44-9. PubMed ID: 2669710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mode of action and clinical pharmacology of gliclazide: a review.
    Campbell DB; Lavielle R; Nathan C
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S21-36. PubMed ID: 1794262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sulfonylureas and platelet function.
    Klaff LJ; Kernoff L; Vinik AI; Jackson WP; Jacobs P
    Am J Med; 1981 Mar; 70(3):627-30. PubMed ID: 6782875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evaluation of the effects of some sulphonylureas on platelet function.
    King JB; Kalk WJ; Vinik AI; Jackson WP; Bracher M; Jacobs P
    S Afr Med J; 1977 Jan; 51(5):124-6. PubMed ID: 322325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Inhibitory effect of gliclazide on platelet adhesiveness and aggregation in alloxan diabetic rabbits (author's transl)].
    Kuwashima J; Tsuboi T; Komiya M; Fujitani B; Nakamura K; Maeda J; Kaneko H; Yoshida K; Shimizu M
    Yakugaku Zasshi; 1979 Jan; 99(1):59-64. PubMed ID: 430345
    [No Abstract]   [Full Text] [Related]  

  • 29. [Metabolic effects of gliclazide in diabetes type II patients. Study with indirect calorimetry].
    Golay A; Broquet C; Chabot V; Studer S; Felber JP
    Schweiz Med Wochenschr; 1984 Feb; 114(8):261-4. PubMed ID: 6369531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of prolonged glyclazide treatment on blood glucose and plasma insulin responses in obese patients with maturity-onset diabetes.
    Wajchenberg BL; Nery M; Leme CE; Silveira AA; Fioratti P; Germek OA
    Clin Pharmacol Ther; 1980 Mar; 27(3):375-8. PubMed ID: 6987025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of insulin therapy on coagulation and platelet function in type II (non-insulin-dependent) diabetes mellitus.
    Small M; Douglas JT; Lowe GD; MacCuish AC; Forbes CD
    Haemostasis; 1986; 16(6):417-23. PubMed ID: 3108103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time course of changes in in vitro platelet function and plasma von willebrand factor activity (VIIIR:WF) and factor VIII-related antigen (VIIIR:Ag) in the diabetic rat.
    Winocour PD; Lopes-Virella M; Laimins M; Colwell JA
    J Lab Clin Med; 1983 Nov; 102(5):795-804. PubMed ID: 6415193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of an oral antidiabetic drug on the fibrinolytic system of blood in insulin-treated diabetic patients.
    Gram J; Jespersen J; Kold A
    Metabolism; 1988 Oct; 37(10):937-43. PubMed ID: 3050364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gliclazide: the effects on lipids in type II diabetes.
    Delargy M; McGovern M; Johnson A; Tomkin GH
    Ir J Med Sci; 1985 Mar; 154(3):102-5. PubMed ID: 3997441
    [No Abstract]   [Full Text] [Related]  

  • 35. The inhibition of cancer cell stickiness, a model for investigation of platelet aggregation inhibitors in vivo. Effect of the sulfonyl urea derivatives, glibenclamide, gliclazide, and HB180, as well as the carboxylic acid derivative, meglitinide.
    Gastpar H; Weissgerber PW; Enzmann F; Zoltobrocki M
    Res Exp Med (Berl); 1982; 180(1):75-84. PubMed ID: 6805052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Free radical scavenging activity of sulfonylureas: a clinical assessment of the effectiveness of gliclazide].
    Jennings PE; Belch JJ
    Ter Arkh; 2001; 73(4):27-31. PubMed ID: 11494442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.
    Palmer KJ; Brogden RN
    Drugs; 1993 Jul; 46(1):92-125. PubMed ID: 7691511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Factor VIII R-Ag and factor VIII Co in diabetes mellitus: correlation between hormonal pattern and type of retinopathy].
    Calle Pascual AL; Bordiu Obanza E; Pérez Villamil B; Martín Alvarez P; Escribá A; Maluenda MP; Espinós D; Marañes JP
    Med Clin (Barc); 1984 Jun; 83(1):4-8. PubMed ID: 6434887
    [No Abstract]   [Full Text] [Related]  

  • 39. Gliclazide increases glucose utilization by rat intestine in vitro.
    Tormo MA; Zubeldia MA; Montero JL; Campillo JE
    Diabete Metab; 1989; 15(4):170-5. PubMed ID: 2806703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Long-term ambulatory treatment of diabetics with gliclazide].
    Parodi FA
    Clin Ter; 1979 Feb; 88(3):281-8. PubMed ID: 376219
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.